Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension
Background: Endothelin-receptor-antagonist, bosentan, has been found to improve the functional capacity and cardiopulmonary hemodynamics in Pulmonary Arterial Hypertension (PAH). Clinical trials have shown the preferable dosage of 125 mg, twice daily, regarding both efficacy and safety. Objectives:...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Wolters Kluwer Medknow Publications
2015-01-01
|
| Reeks: | Research in Cardiovascular Medicine |
| Onderwerpen: | |
| Online toegang: | http://www.rcvmonline.com/article.asp?issn=2251-9572;year=2015;volume=4;issue=3;spage=7;epage=7;aulast=Amin;type=0 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|